ArticleEuropean radiology2026
Photon-counting detector CT with iodine quantification: improved distinction between bland and neoplastic portal vein thrombosis.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNeoplastic portal vein thrombosis (PVT) is a critical prognostic factor in hepatocellular carcinoma (HCC); however, differentiation from bland PVT remains challenging using conventional imaging criteria. Photon-counting detector CT (PCD-CT) enables quantitative iodine density (ID) assessment in every contrast-enhanced acquisition. This study evaluated the diagnostic performance of ID for distinguishing bland from neoplastic PVT. MATERIALS AND
methodsIn this retrospective single-center study, 104 patients with suspected PVT who underwent PCD-CT between 09/2022 and 08/2024 were included. Based on imaging, follow-up data, and multidisciplinary consensus, patients were classified into four groups: HCC with neoplastic PVT (n = 18), HCC with bland PVT (n = 29), bland PVT without malignancy (n = 31), and neoplastic PVT in non-HCC malignancies (n = 26). ID was measured in the late arterial phase (LAP) and portal venous phase (PVP) by two independent radiologists and compared with a CT feature-based score including vessel infiltration, thrombus extension, and arterial hyperenhancement.
resultsID measurements demonstrated excellent inter- and intra-rater agreement (ICC ≥ 0.99). ID was significantly higher in neoplastic PVT in both phases. Diagnostic performance was high, with sensitivities and specificities of 100% and 95.9% in LAP and 93.1% and 100% in PVP (AUC 0.98 (95% CI: 0.95-1.00) and 0.97 (95% CI: 0.92-1.00)). The feature-based score showed lower accuracy. In non-HCC malignancies, ID achieved high diagnostic accuracy in PVP.
conclusionID derived from PCD-CT reliably differentiates neoplastic from bland PVT in HCC and outperforms conventional CT features. In non-HCC malignancies, ID is particularly accurate in the portal venous phase, supporting its broader clinical utility as an imaging biomarker in this contrast media phase. KEY POINTS: Question Can iodine density measured by photon-counting detector CT improve the differentiation between bland and neoplastic portal vein thrombosis? Findings Iodine density measurements obtained with photon-counting CT accurately differentiated neoplastic from bland portal vein thrombosis and outperformed established morphologic CT features. Clinical relevance Photon-counting CT-derived iodine density enables reliable, noninvasive identification of neoplastic portal vein thrombosis, thereby improving diagnostic confidence and treatment planning in patients with hepatocellular carcinoma and other malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.